ACUT (Accustem Sciences) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Days Payable?

Accustem Sciences's average Accounts Payable for the three months ended in Sep. 2024 was $0.77 Mil. Accustem Sciences's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Accustem Sciences's Days Payable or its related term are showing as below:

ACUT's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

Accustem Sciences's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Accustem Sciences Days Payable Historical Data

The historical data trend for Accustem Sciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Days Payable Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Days Payable

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Accustem Sciences's Days Payable

For the Biotechnology subindustry, Accustem Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Days Payable falls into.

Accustem Sciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Accustem Sciences's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.312	+	0.578)	/	2 )	/	0	*	365
=	0.445					/	0	*	365
=	N/A

Accustem Sciences's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0.745	+	0.79)	/	2 )	/	0	*	365 / 4
=	0.7675					/	0	*	365 / 4
=	N/A

Accustem Sciences Days Payable Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001

Website

https://www.accustem.com

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.